Patents by Inventor Prasanna R. Kolatkar

Prasanna R. Kolatkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141299
    Abstract: The instant disclosure relates to methods and compositions for increasing ?-cell production from stem cells.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 2, 2024
    Inventors: Prasanna R. Kolatkar, Essam M. Abdelalim, Noura Aldous, Zeyaul Islam
  • Publication number: 20240052022
    Abstract: Alpha synuclein picobodies, which are N-terminal truncations of alpha synuclein nanobodies are provided. Methods of using alpha synuclein picobodies for diagnosing and treating synucleinopathies are also provided.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 15, 2024
    Inventors: Prasanna R. Kolatkar, Zeyaul Islam, Issam Hmila, Nishant Vaikath, Omar El-Agnaf
  • Patent number: 8907055
    Abstract: There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: December 9, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Prasanna R. Kolatkar, Irene Aksoy, Ralf Jauch, Lawrence W. Stanton
  • Publication number: 20120220029
    Abstract: There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
    Type: Application
    Filed: November 4, 2010
    Publication date: August 30, 2012
    Applicant: Agency for Science, Technology and Research
    Inventors: Prasanna R. Kolatkar, Irene Aksoy, Ralf Jauch, Lawrence W. Stanton